ERBB2 and cancer: We found that for the most commonly diagnosed luminal breast cancers, more than 60% of the cancers were detected in screening and nearly 90% of the cancers were diagnosed at an early stage, while less than 50% of TNBC and HER2-positive breast cancers were diagnosed by screening.